Use of the comet assay technique for quick and reliable prediction of in vitro response to chemotherapeutics in breast and colon cancer

Panagiotis Apostolou, Maria Toloudi, Eleni Kourtidou, Georgia Mimikakou, Ioanna Vlachou, Marina Chatziioannou and Ioannis Papasotiriou*

Abstract

Background: Determination of response to chemotherapy is a major requirement of personalized medicine. Resistance, whether developed or native, critically affects a treatment’s success. Single Cell Gel Electrophoresis - also known as a comet assay - is used to detect DNA damage at the level of individual eukaryotic cells. We assessed the use of comet assays in determining response to chemotherapeutic drugs that are widely used in breast and colon cancer.

Results: We treated human breast and colon cancer cell lines with melphalan, cisplatin, mechlorethamine or doxorubicin, as monotherapies. Drug activities varied even in the same cancer types, further demonstrating the heterogeneity of different cancer types.

Conclusion: The comet assay technique can provide reliable and quick results with minimum requirements and is applicable to a wide variety of drugs.

Keywords: Comet assay, Personalized medicine, Breast cancer, Colon cancer, Cisplatin, Melphalan, Mechlorethamine, Doxorubicin

Background

Personalized medicine requires that therapy should be customized to individual patients, using genetic or other information [1]. Prediction of response to chemotherapy drugs is a major concern in cancer treatment [2]. Resistance to chemotherapy agents may exist before, or develop during, therapy [3]. Most techniques to predict response entail analysis of expression of different genes [4]. However, fast, reliable results are urgently needed; moreover, a drug's effect cannot always be predicted by measuring gene expression [5].

Single Cell Gel Electrophoresis (SCGE), also known as comet assay can measure DNA damage in individual eukaryotic cells. The principle of the comet assay is that unfragmented DNA maintains a well-organized structure in the nucleus, but becomes disrupted when the cell is damaged. It detects both single-strand and double-strand breaks, and has a simple and inexpensive setup. Comet assay is therefore a promising technique for predicting response to drugs that are affected by DNA structure [6].

The present study evaluated the predictability of response to widely used chemotherapy drug from comet assay results in established human breast and colon cancer cell lines. We tested nitrogen-mustard alkylating agents (melphalan, mechlorethamine) and doxorubicin in breast cancer, and tested cisplatin in colon cancer cell lines.

Results and discussion

Analysis of results was based on percentages of DNA in the comet “head” (amount of genetic material distributed in the nucleus) and in “tail” (amount of genetic material distributed in the fragmented pieces). We examined ≥ 100 cells for each combination of cells and drugs. With p set to be 0.05, we estimated the ranges of DNA percentage in untreated and treated cells; where these ranges overlapped, the cells were rejected. In the MCF-7 and MDA-MB 231 cell lines, we clearly observed functional activity for all drugs. The T47D cells showed
Apostolou et al. Journal of Biological Research-Thessaloniki 2014, 21:14 http://www.jbiolres.com/content/21/1/14

Table 1 DNA (%) presented in “head” and “tail” pre- and post-incubation with doxorubicin in breast cancer cell lines

| Cell Line | Control % DNA (mean ± 1.96 S.E.) | Cisplatin (1 μM) % DNA (mean ± 1.96 S.E.) | % DNA in Head | % DNA in Tail |
|-----------|----------------------------------|------------------------------------------|---------------|--------------|
| LoVo      | 83.55 ± 4.25                     | 89.28 ± 2.32                             | 17.45 ± 4.12  | 11.72 ± 2.29 |
| HCT-15    | 78.58 ± 4.05                     | 92.35 ± 1.84                             | 21.42 ± 4.05  | 8.51 ± 1.88  |
| HCT-15    | 84.92 ± 3.32                     | 92.50 ± 2.00                             | 15.08 ± 3.27  | 8.51 ± 1.88  |
| HT55      | 82.17 ± 2.75                     | 90.60 ± 2.15                             | 17.82 ± 2.75  | 9.39 ± 1.51  |

Table 2 DNA (%) presented in “head” and “tail” pre- and post-incubation with melphalan in breast cancer cell lines

| Cell Line | Control % DNA (mean ± 1.96 S.E.) | Melphalan (1 μM) % DNA (mean ± 1.96 S.E.) | % DNA in Head | % DNA in Tail |
|-----------|----------------------------------|------------------------------------------|---------------|--------------|
| MCF-7     | 66.43 ± 3.68                     | 83.96 ± 2.42                             | 33.56 ± 3.68  | 16.04 ± 2.35 |
| MDA-MB 231| 77.14 ± 2.98                     | 82.66 ± 2.33                             | 22.85 ± 2.98  | 17.34 ± 2.33 |
| T47D      | 77.87 ± 2.60                     | 85.37 ± 1.93                             | 22.12 ± 2.60  | 14.62 ± 1.93 |

Table 3 DNA (%) presented in “head” and “tail” pre- and post-incubation with mechlorethamine in breast cancer cell lines

| Cell Line | Control % DNA (mean ± 1.96 S.E.) | Mechlorethamine (0.1 μM) % DNA (mean ± 1.96 S.E.) | % DNA in Head | % DNA in Tail |
|-----------|----------------------------------|--------------------------------------------------|---------------|--------------|
| MCF-7     | 71.03 ± 4.16                     | 83.71 ± 2.31                                     | 28.96 ± 4.16  | 16.64 ± 2.26 |
| MDA-MB 231| 71.83 ± 2.49                     | 86.72 ± 1.52                                     | 28.16 ± 2.49  | 13.43 ± 1.49 |
| T47D      | 84.64 ± 2.77                     | 85.75 ± 2.11                                     | 84.64 ± 2.77  | 14.24 ± 2.11 |

Table 4 DNA (%) presented in “head” and “tail” pre- and post-incubation with doxorubicin in breast cancer cell lines

| Cell Line | Control % DNA (mean ± 1.96 S.E.) | Doxorubicin (1 μM) % DNA (mean ± 1.96 S.E.) | % DNA in Head | % DNA in Tail |
|-----------|----------------------------------|------------------------------------------|---------------|--------------|
| MCF-7     | 66.43 ± 3.68                     | 81.33 ± 2.67                             | 33.56 ± 3.68  | 19.17 ± 2.62 |
| MDA-MB 231| 77.14 ± 2.98                     | 83.93 ± 1.94                             | 22.85 ± 2.98  | 16.06 ± 1.94 |
| T47D      | 77.87 ± 2.60                     | 83.17 ± 2.27                             | 22.12 ± 2.60  | 16.82 ± 2.27 |

functional activity for melphalan and doxorubicin, but not for mechlorethamine. All the colorectal cancer cell lines except LoVo, were also successfully affected (Tables 1, 2, 3 and 4; Figures 1, 2 and 3).

Comet visual scoring can be also calculated based on a five-grade scale from 0 to 4. In a grade 4 comet cell, the entire DNA is in the “tail”, while in grade 0 the entire DNA is in “head”. These values given to comets can be summarized and provide a quantitative measure for 100 cells on a scale from 0–400. These data are presented in Figure 4. A high score means that the cells have been fragmented by repair enzymes. Alkylating agents can also induce mispairing of nucleotides. As the mode of action depends on the genetic structure, a means of detecting changes in DNA structure is needed [11]. Nitrogen mustards are non-specific cytotoxic chemotherapy agents, and include cyclophosphamide, chlorambucil, uramustine, ifosfamide, melphalan, bendamustine and mechlorethamine [12].

Melphalan in combination with other drugs, or as monotherapy, is highly active in patients with advanced breast cancer. It attaches an alkyl group to the 7 nitrogen atom of the imidazole ring, in the DNA guanine base. Melphalan has several side effects including leukopenia, thrombocytopenia and anemia, nausea, vomiting and diarrhea [13]. Mechlorethamine also known as mustine (HN2) is a derivative of mustard gas. It prevents cell duplication by cross linking DNA; it is cell cycle phase-nonspecific. It is used in humans and other mammals. Overexposure can lead to leukopenia, anemia and thrombocytopenia, while chromosomal abnormalities, hepatotoxicity, neurotoxicity and cardiac irregularities have been reported; both its hematologic and gastrointestinal side effects are usually dose-dependent. [14].
**Figure 1** Comet assay data for MDA-MB 231 cell line.  
A: Untreated cell line after alkaline lysis.  
B: The percentage of DNA in tail has been reduced after incubation with doxorubicin.  
C: Data after incubation with melphalan.  
D: Treatment with mechlorethamine.

**Figure 2** Comet assay data for cancer cell lines representing colorectal cancer.  
A: Control HCT-15 cell line without cisplatin.  
B: HCT-15 after incubation with cisplatin.  
C: Untreated HCT-116 cell line.  
D: HCT-116 with cisplatin.  
E: LoVo cancer cell line without addition of drugs.  
F: The percentage of DNA in tail is reduced after cisplatin incubation; however the data are not significant.
Neurotoxicity in the form of local-regional sensory has been observed especially in combination with cisplatin (CDDP). Cisplatin binds to DNA to cause cross linking, which leads to apoptosis; it is often combined with other chemotherapy drugs in cancer treatment [15]. In breast cancer, an anthracycline antibiotic is also used; it inhibits the enzyme topoisomerase II, thus inhibiting transcription. Doxorubicin (trade name Adriamycin) is often used in chemotherapy combinations such as AC (doxorubicin-cytoxan), ATC (doxorubicin-cyclophosphamide-Taxol), AT (doxorubicin-taxotere), and FAC (fluorouracil-doxorubicin-cytoxan) [16,17]. Dose-limiting side effects, such as myelosuppression and cardiotoxicity, have been reported after treatment with doxorubicin [18]. Excluding side effects can greatly improve healing of carcinomas. Recent studies have indicated that MAP kinases play an important role in resistance to treatment with doxorubicin, mechlorethamine, paclitaxel and proteasome inhibitors [19].

Many techniques to predict chemotherapy response are available. Assays based on PCR can show genes for enzymes that affect metabolism of these drugs, and can therefore indicate response to a given agent [20,21]. However, they predict response at a genomic level, which often deviates significantly from protein and cellular levels. On the other hand, the study of a great number of proteins displays many restrictions. First, we need high amounts of proteins, which mean a lot of genetic material. Furthermore, the use of Western Blot technique is intended for a limited number of proteins. Additionally, the response to chemotherapy drugs is affected by many alleles (CYB2D6, CYP2C19, CYP3A4 etc.), so the study of all of them in most cases is expensive and time-consuming. Other techniques are based on molecular imaging, such as 18 F-fluorodeoxyglucose-positron emission tomography (18-FDG-PET) or magnetic resonance imaging (MRI) [22], but these methods have common adverse effects. Both techniques are non-invasive, however 18-FDG-PET involves exposure to ionizing radiation and the MRI environment may cause harm in patients by using strong magnetic fields and radiowaves. Comet assay require only a few of a patient’s cells, which can be easily isolated from whole blood. By administrating the chemotherapy agents and then applying an electric field to the DNA, unfragmented DNA moves slowly because it is too large, whereas fragmented parts move faster because of their lighter molecular weight and dense conformation. Unfragmented DNA is thus distributed in the nucleus - the comet’s “head” - and fragmented pieces in the “tail”. The comparative percentage of DNA in a single cell’s “head” and “tail” reflects the effect of a drug on its DNA chains. These percentages are ascertained from the assignment of the pixels in photographs of the assay, as a percentage with no units [23]. By analyzing the above data from many cells, the effect of a drug can be determined. This method can be used also to study genetic instability, or genotoxicity [24,25]. Comet assays can be used to determine bladder cancer cell radiation as well as radiosensitivity in other types of cancer [26].

This particular work contains numerous cancer cell lines, which represent two widespread types of cancer.

**Figure 3 Comet assay data by using the Comet Score software.** The pink represent the DNA in nucleus, while the orange the fragmented DNA. A: Control MCF-7 cell line. B: MCF-7 after incubation with doxorubicin. C: The same cell line post-incubation with melphalan. The percentage of DNA in tail has been reduced, indicating the effect from the drugs.
For each cancer type cell lines with different properties were tested. Also there is a study of several most common chemotherapeutic drugs.

The experimental data demonstrated that personalized treatment is essential in cancer treatment. The data from colon cancer cell lines indicated that cisplatin does not affect each cell line to the same grade. Also, in some cases, like LoVo, the cisplatin is probably ineffective. Between HCT-15 and LoVo, which both represent colon adenocarcinoma, completely different data were observed. However, it is remarkable that LoVo derived from a metastatic tumour. Recent literature data, indicate that cisplatin in combination with other agents is more effective than monotherapy in this particular cell line [27].

Among the breast cancer cell lines, the T47D cells carry receptors for a variety of steroids, while MCF-7 cells express oestrogen receptors. The variety between these receptors may explain the different response to chemotherapy. MDA-MB 231 established from a pleural effusion of a 51 year old woman with metastatic breast cancer, indicating that mechlorethamine might be more effective in metastatic breast tumour.

Comet assays are a sensitive means of detecting both single strand and double strand DNA damage, using only a few cells. Our results here reinforced the heterogeneity of cancer by showing how the effectiveness of each drug varied in each cell line, even when derived from the same cancer type. Potentially, comet assays could allow physicians to evaluate patient response in advance, thus avoiding inappropriate therapies with undesired effects. SCGE is a relatively quick versatile, simple-to-perform technique with a few requirements.

Conclusion
Tailor-made therapy is a promising theme in translational cancer research. However, identifying optimal treatment for an individual patient can be difficult, time-consuming and expensive. Here, we evaluated the effectiveness of comet assays on four commonly used chemotherapeutic drugs, and found that this technique can predict responses of different cancers to the subject drugs and generally to drugs with the same mechanisms of action. Further studies with a wider variety of tumor
cell types and drugs are required to establish the clinical utility of comet assays in selecting cancer treatments.

**Methods**

**Cell lines**

We used human breast cancer cell lines MCF-7, MDA-MB 231 and T47D, and colon cancer cell lines HCT-116, HT55, HCT-15 and LoVo, which came from the European Collection of Cell Cultures (ECACC - HPA cultures, UK). Cells were cultured in 75 cm² flasks (5520200; Orange Scientific) at 37°C in a 5% CO₂ atmosphere, in the recommended media supplemented with the appropriate amount of heat-inactivated fetal bovine serum (Invitrogen, 10106-169, California) and 2 mM L-glutamine (Sigma, G5792, Germany).

**Drugs**

According to literature data, the optimal concentration of each drug varies by cell type and cancer type. Cells were cultured in 12-well plates (3513, Corning) in different concentrations (0.01-50 μM) for each drug. Their viability was analyzed with propidium iodide staining after 24 hrs of incubation (NucleoCounter® NC-100™, Chemometec). Concentrations that were chosen for further experiments were 0.1 μM for mechloethamine (122564, Sigma-Aldrich), 1 μM for melphalan (M2011, Sigma-Aldrich), 1 μM for doxorubicin (D1515, Sigma-Aldrich) and 1 μM for cisplatin (P4394, Sigma-Aldrich).

**Comet Assay**

Cells were divided into 25 cm² flasks (5520100, Orange Scientific), one for each drug and one with no drug added. After 24 hrs of incubation, cells were detached by trypsinization (Trypsin-0.25% EDTA, 25200-072; Invitrogen) and 20000 cells were used for single cell gel electrophoresis with IKZUS comet assay kit (0905-050-K, TriTek Corp., USA). Alkaline lysis of the cells was performed according to instructions. Slides were observed under a UV microscope. Data were analyzed with Comet Score software (TriTek Corp., USA).

**Abbreviations**

SCGE: Single cell gel electrophoresis; HN2: Mustine; CDDP: Cisplatin; AC: Doxorubicin-Cytosan; ATC: Doxorubicin-Cyclophosphamide-Taxol; AT: Doxorubicin-Taxotere; FAC: Fluorouracil-Doxorubicin-Cytosan; 18 F-FDG-PET: 18 F-Fluorodeoxyglucose positron emission tomography; MRI: Magnetic resonance imaging; SE: Standard Error.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

PA carried out the comet assay, drafted the manuscript and performed the statistical analysis. MT participated in cell lines culturing. EK participated in comet assay, GM participated in comet assay, IV participated in cell line culturing. MC participated in drugs preparation, IP supervised the assays and the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

The authors thank the two anonymous referees whose valuable commentary allowed us to improve the manuscript.

Received: 4 March 2014 Accepted: 25 June 2014

**References**

1. Ogino S, Fuchs CS, Giovannucci E: How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012, 12:621-628.
2. Tofilon PJ, Basic J, Miles L: Prediction of in vitro tumor response to chemotherapeutic agents by the in vitro sister chromatid exchange assay. Cancer Res 1985, 45:2025–2030.
3. Liu FS: Mechanisms of chemotherapeutic drug resistance in cancer therapy-a quick review. Taiwan J Obstet Gynecol 2009, 48:239–244.
4. Ochi K, Daigo Y, Katagiri T, Nagayama S, Tsunoda T, Myou A, Naka N, Araki N, Kudawara I, Leguchi M, Tsyama Y, Toguchida J, Yoshikawa H, Nakamura Y: Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol 2004, 24:647–655.
5. Borst P, Wessels L: Do predictive signatures really predict response to cancer chemotherapy? Cell Cycle 2010, 9:4836–4840.
6. Singh NP, McCoy MT, Tice RR, Schneider EL: A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988, 175:184–191.
7. DeSantis C, Ma J, Bryan L, Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin 2014, 64:52–62.
8. Haggard FR, Boushey RP: Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009, 22:191–197.
9. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N: Colorectal cancer. Lancet 2010, 375:1030–1047.
10. Wasserberg N, Kaufman HS: Palliation of colorectal cancer. Surg Oncol 2007, 16:299–310.
11. Warwick GP: The mechanism of action of alkylating agents. Cancer Res 1963, 23:1315–1333.
12. Kamofsky DA: Nitrogen mustards in the treatment of neoplastic disease. Adv Intern Med 1950, 41:1–75.
13. Carpenter JT Jr, Maddox WA: Melphalan adjuvant therapy in breast cancer. Lancet 1983, 2:450–451.
14. Tormey DC: Combined chemotherapy and surgery in breast cancer: a review. Cancer 1975, 36:881–892.
15. Rosenberg B, VanCamp L, Trasko JE, Mansour VH: Platinum compounds: a new class of potent antitumour agents. Nature 1969, 222:385–386.
16. Prados J, Melguizo C, Ortiz R, Vélez C, Alvarez PJ, Arias JL, Ruiz MA, Gallardo V, Aranega A: Doxorubicin-loaded nanoparticles: new advances in breast cancer therapy. Anticancer Agents Med Chem 2012, 12:1058–1070.
17. Di Marco A, Gaetani M, Scarpinato B: Doxorubicin cardiomyopathy. Cancer Chemother Rep 1969, 53:33–37.
18. Chatterjee K, Zhang J, Honbor N, Khatr LN: Doxorubicin cardiomyopathy. Cardiology 2010, 115:155–162.
19. Hagemann KK, Wu GS: The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev 2010, 29:143–149.
20. Denkert C, Loibl S, Kronenwett R, Budzies J, von Törne C, Nekljudova V, Darb-Esfahani S, Dalsgaard C, Onitz C, Votava T, Untch M, von Minckwitz G: RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy. Ann Oncol 2013, 24:632–639.
21. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt K, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA: Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 2013, 24:1999–2004.
22. Tateishi U, Miyake M, Nagaoka T, Terauchi T, Kubota K, Kinoshita T, Datski H, Macapinlac HA: Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging-prospective assessment. Radiology 2012, 263:53–63.
24. Brendler-Schwaab S, Hartmann A, Pfuhler S, Speit G: The in vivo comet assay: use and status in genotoxicity testing. Mutagenesis 2005, 20:245–254.

25. Schabath MB, Spitz MR, Grossman HB, Zhang K, Dinney CP, Zheng PJ, Wu X: Genetic instability in bladder cancer assessed by the comet assay. J Natl Cancer Inst 2003, 95:540–547.

26. McKeown SR, Robson T, Price ME, Ho ET, Hirst DG, McKelvey-Martin VJ: Potential use of the alkaline comet assay as a predictor of bladder tumour response to radiation. Br J Cancer 2003, 89:2264–2270.

27. Lin HH, Shi MD, Tseng HC, Chen JH: Andrographolide sensitizes the cytotoxicity of human colorectal carcinoma cells toward cisplatin via enhancing apoptosis pathways in vitro and in vivo. Toxicol Sci 2014, 139:108–120.

doi:10.1186/2241-5793-21-14

Cite this article as: Apostolou et al: Use of the comet assay technique for quick and reliable prediction of in vitro response to chemotherapeutics in breast and colon cancer. Journal of Biological Research-Thessaloniki 2014 21:14.